Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Willing and able to give written informed consent.

          -  Have histologically or cytologically confirmed advanced or metastatic solid tumor with
             a relevant molecular alteration (as applicable).

          -  There is no available standard systemic therapy available for the patient's tumor
             histology and/or molecular biomarker profile; or standard therapy is intolerable, not
             effective, or not accessible; or patient has refused standard therapy.

          -  Recovered from all toxicities associated with prior treatment to acceptable baseline
             status.

          -  Have ECOG performance status of 0 or 1 with an anticipated life expectancy of > 12
             weeks.

          -  Willing to comply with all protocol-required visits, assessments, and procedures.

          -  Able to swallow tablets.

        Exclusion Criteria:

          -  Currently receiving another study therapy or has participated in a study of an
             investigational agent and received study therapy within 4 weeks of the first dose of
             ERAS-007.

          -  Received previous treatment with an ERK inhibitor.

          -  Received prior antineoplastic therapy within < 21 days or 5 half-lives, whichever is
             shorter.

          -  Received prior palliative radiation within 7 days of first dose of ERAS 007.

          -  Received previous treatment with a MAPK inhibitor that resulted in discontinuation due
             to unacceptable toxicity.

          -  Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal
             dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may
             affect drug absorption.

          -  Have any underlying medical condition, psychiatric condition, or social situation
             that, in the opinion of the Investigator, would compromise study administration as per
             protocol or compromise the assessment of AEs.

          -  Are pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the trial.